Targeted screening for congenital cytomegalovirus: A micro‐costing analysis
Aim We aimed to determine the cost and potential cost‐savings of delivering a targeted congenital cytomegalovirus (cCMV) screening programme through a universal newborn hearing screening (UNHS) programme to detect cCMV‐related hearing loss in infants from Victoria, Australia. Methods We completed a...
Gespeichert in:
| Veröffentlicht in: | Journal of paediatrics and child health 2023-01, Vol.59 (1), p.64-71 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 71 |
|---|---|
| container_issue | 1 |
| container_start_page | 64 |
| container_title | Journal of paediatrics and child health |
| container_volume | 59 |
| creator | Gillespie, Alanna N Dalziel, Kim Webb, Emma Wong, Janis Jones, Cheryl A Sung, Valerie |
| description | Aim
We aimed to determine the cost and potential cost‐savings of delivering a targeted congenital cytomegalovirus (cCMV) screening programme through a universal newborn hearing screening (UNHS) programme to detect cCMV‐related hearing loss in infants from Victoria, Australia.
Methods
We completed a micro‐costing analysis from a health‐care perspective using data from a targeted cCMV screening programme piloted between June 2019 and March 2020. The programme involved collection of saliva samples to test for cCMV in infants who: received a ‘refer’ result on their second newborn hearing screen; were aged 21 days or less; and born at one of four maternity hospitals in Victoria, Australia. All costs to complete targeted cCMV screening were recorded in Australian 2020 dollars. Potential costs and benefits of adding targeted cCMV screening to the pre‐existing UNHS programme were compared to when no screening was available up to 18 years to determine the likely cost or cost savings.
Results
The cost of adding targeted cCMV screening to Victoria's UNHS is $202 per infant screened. The total cost per positive case identified is $21 456. The overall cost of adding targeted salivary cCMV screening at the point of a second ‘refer’ result on the UNHS programme in Victoria's four largest hospitals is estimated to be $28 966 for the first year.
Conclusion
Targeted screening for cCMV provides families the opportunity to detect and, if appropriate, treat cCMV in the first month of life in line with current recommendations. It falls within the range between cost neutral and cost saving. |
| doi_str_mv | 10.1111/jpc.16239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10946837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763420556</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4449-a753b38d48dcb62c091f32591f3f06a1b6565bc8990e3503880fb412105738cb3</originalsourceid><addsrcrecordid>eNp1kctOxCAYRonReF_4AqaJG11UuZe6MWbiNRpdjGtCGVqZtGWEVjM7H8Fn9ElknNGoiSy4hMPhhw-AHQQPUWxH44k-RByTfAmsI0phijJGl-McEppSgeAa2AhhDCHEjIlVsEY4ZpBxvA5uh8pXpjOjJGhvTGvbKimdT7Rrq7jqVJ3oaecaU6naPVvfh-PkNGms9u799U270M1OqFbV02DDFlgpVR3M9mLcBA_nZ8PBZXpzd3E1OL1JNaU0T1XGSEHEiIqRLjjWMEclwWzWl5ArVHDGWaFFnkNDGCRCwLKgCCPIMiJ0QTbBydw76YvGjLRpO69qOfG2UX4qnbLy905rH2XlniWCOeWCZNGwvzB499Sb0MnGBm3qWrXG9UHiDDNKcbw7ont_0LHrfXzxjOIkQozxSB3MqfgzIXhTfleDoJylJGNK8jOlyO7-LP-b_IolAkdz4MXWZvq_SV7fD-bKD_GynJE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2763420556</pqid></control><display><type>article</type><title>Targeted screening for congenital cytomegalovirus: A micro‐costing analysis</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Gillespie, Alanna N ; Dalziel, Kim ; Webb, Emma ; Wong, Janis ; Jones, Cheryl A ; Sung, Valerie</creator><creatorcontrib>Gillespie, Alanna N ; Dalziel, Kim ; Webb, Emma ; Wong, Janis ; Jones, Cheryl A ; Sung, Valerie ; HearS-cCMV Project ; the HearS‐cCMV Project</creatorcontrib><description>Aim
We aimed to determine the cost and potential cost‐savings of delivering a targeted congenital cytomegalovirus (cCMV) screening programme through a universal newborn hearing screening (UNHS) programme to detect cCMV‐related hearing loss in infants from Victoria, Australia.
Methods
We completed a micro‐costing analysis from a health‐care perspective using data from a targeted cCMV screening programme piloted between June 2019 and March 2020. The programme involved collection of saliva samples to test for cCMV in infants who: received a ‘refer’ result on their second newborn hearing screen; were aged 21 days or less; and born at one of four maternity hospitals in Victoria, Australia. All costs to complete targeted cCMV screening were recorded in Australian 2020 dollars. Potential costs and benefits of adding targeted cCMV screening to the pre‐existing UNHS programme were compared to when no screening was available up to 18 years to determine the likely cost or cost savings.
Results
The cost of adding targeted cCMV screening to Victoria's UNHS is $202 per infant screened. The total cost per positive case identified is $21 456. The overall cost of adding targeted salivary cCMV screening at the point of a second ‘refer’ result on the UNHS programme in Victoria's four largest hospitals is estimated to be $28 966 for the first year.
Conclusion
Targeted screening for cCMV provides families the opportunity to detect and, if appropriate, treat cCMV in the first month of life in line with current recommendations. It falls within the range between cost neutral and cost saving.</description><identifier>ISSN: 1034-4810</identifier><identifier>EISSN: 1440-1754</identifier><identifier>DOI: 10.1111/jpc.16239</identifier><identifier>PMID: 36250562</identifier><language>eng</language><publisher>Australia: John Wiley & Sons Australia, Ltd</publisher><subject>congenital cytomegalovirus ; Cost control ; Cytomegalovirus ; Cytomegalovirus - genetics ; Cytomegalovirus Infections - congenital ; Cytomegalovirus Infections - diagnosis ; Female ; Health care expenditures ; hearing loss ; Hearing Loss, Sensorineural - diagnosis ; Humans ; Infant ; Infant, Newborn ; Medical screening ; micro‐costing ; Neonatal Screening ; Newborn babies ; Original ; Pediatrics ; Pregnancy ; targeted screening ; Victoria</subject><ispartof>Journal of paediatrics and child health, 2023-01, Vol.59 (1), p.64-71</ispartof><rights>2022 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Paediatrics and Child Health Division (The Royal Australasian College of Physicians).</rights><rights>2022 The Authors. Journal of Paediatrics and Child Health published by John Wiley & Sons Australia, Ltd on behalf of Paediatrics and Child Health Division (The Royal Australasian College of Physicians).</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4449-a753b38d48dcb62c091f32591f3f06a1b6565bc8990e3503880fb412105738cb3</citedby><cites>FETCH-LOGICAL-c4449-a753b38d48dcb62c091f32591f3f06a1b6565bc8990e3503880fb412105738cb3</cites><orcidid>0000-0003-2029-6331 ; 0000-0003-4544-1830 ; 0000-0003-3225-3849</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjpc.16239$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjpc.16239$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36250562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gillespie, Alanna N</creatorcontrib><creatorcontrib>Dalziel, Kim</creatorcontrib><creatorcontrib>Webb, Emma</creatorcontrib><creatorcontrib>Wong, Janis</creatorcontrib><creatorcontrib>Jones, Cheryl A</creatorcontrib><creatorcontrib>Sung, Valerie</creatorcontrib><creatorcontrib>HearS-cCMV Project</creatorcontrib><creatorcontrib>the HearS‐cCMV Project</creatorcontrib><title>Targeted screening for congenital cytomegalovirus: A micro‐costing analysis</title><title>Journal of paediatrics and child health</title><addtitle>J Paediatr Child Health</addtitle><description>Aim
We aimed to determine the cost and potential cost‐savings of delivering a targeted congenital cytomegalovirus (cCMV) screening programme through a universal newborn hearing screening (UNHS) programme to detect cCMV‐related hearing loss in infants from Victoria, Australia.
Methods
We completed a micro‐costing analysis from a health‐care perspective using data from a targeted cCMV screening programme piloted between June 2019 and March 2020. The programme involved collection of saliva samples to test for cCMV in infants who: received a ‘refer’ result on their second newborn hearing screen; were aged 21 days or less; and born at one of four maternity hospitals in Victoria, Australia. All costs to complete targeted cCMV screening were recorded in Australian 2020 dollars. Potential costs and benefits of adding targeted cCMV screening to the pre‐existing UNHS programme were compared to when no screening was available up to 18 years to determine the likely cost or cost savings.
Results
The cost of adding targeted cCMV screening to Victoria's UNHS is $202 per infant screened. The total cost per positive case identified is $21 456. The overall cost of adding targeted salivary cCMV screening at the point of a second ‘refer’ result on the UNHS programme in Victoria's four largest hospitals is estimated to be $28 966 for the first year.
Conclusion
Targeted screening for cCMV provides families the opportunity to detect and, if appropriate, treat cCMV in the first month of life in line with current recommendations. It falls within the range between cost neutral and cost saving.</description><subject>congenital cytomegalovirus</subject><subject>Cost control</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus - genetics</subject><subject>Cytomegalovirus Infections - congenital</subject><subject>Cytomegalovirus Infections - diagnosis</subject><subject>Female</subject><subject>Health care expenditures</subject><subject>hearing loss</subject><subject>Hearing Loss, Sensorineural - diagnosis</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Medical screening</subject><subject>micro‐costing</subject><subject>Neonatal Screening</subject><subject>Newborn babies</subject><subject>Original</subject><subject>Pediatrics</subject><subject>Pregnancy</subject><subject>targeted screening</subject><subject>Victoria</subject><issn>1034-4810</issn><issn>1440-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctOxCAYRonReF_4AqaJG11UuZe6MWbiNRpdjGtCGVqZtGWEVjM7H8Fn9ElknNGoiSy4hMPhhw-AHQQPUWxH44k-RByTfAmsI0phijJGl-McEppSgeAa2AhhDCHEjIlVsEY4ZpBxvA5uh8pXpjOjJGhvTGvbKimdT7Rrq7jqVJ3oaecaU6naPVvfh-PkNGms9u799U270M1OqFbV02DDFlgpVR3M9mLcBA_nZ8PBZXpzd3E1OL1JNaU0T1XGSEHEiIqRLjjWMEclwWzWl5ArVHDGWaFFnkNDGCRCwLKgCCPIMiJ0QTbBydw76YvGjLRpO69qOfG2UX4qnbLy905rH2XlniWCOeWCZNGwvzB499Sb0MnGBm3qWrXG9UHiDDNKcbw7ont_0LHrfXzxjOIkQozxSB3MqfgzIXhTfleDoJylJGNK8jOlyO7-LP-b_IolAkdz4MXWZvq_SV7fD-bKD_GynJE</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Gillespie, Alanna N</creator><creator>Dalziel, Kim</creator><creator>Webb, Emma</creator><creator>Wong, Janis</creator><creator>Jones, Cheryl A</creator><creator>Sung, Valerie</creator><general>John Wiley & Sons Australia, Ltd</general><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2029-6331</orcidid><orcidid>https://orcid.org/0000-0003-4544-1830</orcidid><orcidid>https://orcid.org/0000-0003-3225-3849</orcidid></search><sort><creationdate>202301</creationdate><title>Targeted screening for congenital cytomegalovirus: A micro‐costing analysis</title><author>Gillespie, Alanna N ; Dalziel, Kim ; Webb, Emma ; Wong, Janis ; Jones, Cheryl A ; Sung, Valerie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4449-a753b38d48dcb62c091f32591f3f06a1b6565bc8990e3503880fb412105738cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>congenital cytomegalovirus</topic><topic>Cost control</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus - genetics</topic><topic>Cytomegalovirus Infections - congenital</topic><topic>Cytomegalovirus Infections - diagnosis</topic><topic>Female</topic><topic>Health care expenditures</topic><topic>hearing loss</topic><topic>Hearing Loss, Sensorineural - diagnosis</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Medical screening</topic><topic>micro‐costing</topic><topic>Neonatal Screening</topic><topic>Newborn babies</topic><topic>Original</topic><topic>Pediatrics</topic><topic>Pregnancy</topic><topic>targeted screening</topic><topic>Victoria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gillespie, Alanna N</creatorcontrib><creatorcontrib>Dalziel, Kim</creatorcontrib><creatorcontrib>Webb, Emma</creatorcontrib><creatorcontrib>Wong, Janis</creatorcontrib><creatorcontrib>Jones, Cheryl A</creatorcontrib><creatorcontrib>Sung, Valerie</creatorcontrib><creatorcontrib>HearS-cCMV Project</creatorcontrib><creatorcontrib>the HearS‐cCMV Project</creatorcontrib><collection>Wiley Online Library</collection><collection>Wiley Online Library</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of paediatrics and child health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gillespie, Alanna N</au><au>Dalziel, Kim</au><au>Webb, Emma</au><au>Wong, Janis</au><au>Jones, Cheryl A</au><au>Sung, Valerie</au><aucorp>HearS-cCMV Project</aucorp><aucorp>the HearS‐cCMV Project</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted screening for congenital cytomegalovirus: A micro‐costing analysis</atitle><jtitle>Journal of paediatrics and child health</jtitle><addtitle>J Paediatr Child Health</addtitle><date>2023-01</date><risdate>2023</risdate><volume>59</volume><issue>1</issue><spage>64</spage><epage>71</epage><pages>64-71</pages><issn>1034-4810</issn><eissn>1440-1754</eissn><abstract>Aim
We aimed to determine the cost and potential cost‐savings of delivering a targeted congenital cytomegalovirus (cCMV) screening programme through a universal newborn hearing screening (UNHS) programme to detect cCMV‐related hearing loss in infants from Victoria, Australia.
Methods
We completed a micro‐costing analysis from a health‐care perspective using data from a targeted cCMV screening programme piloted between June 2019 and March 2020. The programme involved collection of saliva samples to test for cCMV in infants who: received a ‘refer’ result on their second newborn hearing screen; were aged 21 days or less; and born at one of four maternity hospitals in Victoria, Australia. All costs to complete targeted cCMV screening were recorded in Australian 2020 dollars. Potential costs and benefits of adding targeted cCMV screening to the pre‐existing UNHS programme were compared to when no screening was available up to 18 years to determine the likely cost or cost savings.
Results
The cost of adding targeted cCMV screening to Victoria's UNHS is $202 per infant screened. The total cost per positive case identified is $21 456. The overall cost of adding targeted salivary cCMV screening at the point of a second ‘refer’ result on the UNHS programme in Victoria's four largest hospitals is estimated to be $28 966 for the first year.
Conclusion
Targeted screening for cCMV provides families the opportunity to detect and, if appropriate, treat cCMV in the first month of life in line with current recommendations. It falls within the range between cost neutral and cost saving.</abstract><cop>Australia</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>36250562</pmid><doi>10.1111/jpc.16239</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2029-6331</orcidid><orcidid>https://orcid.org/0000-0003-4544-1830</orcidid><orcidid>https://orcid.org/0000-0003-3225-3849</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1034-4810 |
| ispartof | Journal of paediatrics and child health, 2023-01, Vol.59 (1), p.64-71 |
| issn | 1034-4810 1440-1754 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10946837 |
| source | MEDLINE; Wiley Online Library |
| subjects | congenital cytomegalovirus Cost control Cytomegalovirus Cytomegalovirus - genetics Cytomegalovirus Infections - congenital Cytomegalovirus Infections - diagnosis Female Health care expenditures hearing loss Hearing Loss, Sensorineural - diagnosis Humans Infant Infant, Newborn Medical screening micro‐costing Neonatal Screening Newborn babies Original Pediatrics Pregnancy targeted screening Victoria |
| title | Targeted screening for congenital cytomegalovirus: A micro‐costing analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A51%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20screening%20for%20congenital%20cytomegalovirus:%20A%20micro%E2%80%90costing%20analysis&rft.jtitle=Journal%20of%20paediatrics%20and%20child%20health&rft.au=Gillespie,%20Alanna%20N&rft.aucorp=HearS-cCMV%20Project&rft.date=2023-01&rft.volume=59&rft.issue=1&rft.spage=64&rft.epage=71&rft.pages=64-71&rft.issn=1034-4810&rft.eissn=1440-1754&rft_id=info:doi/10.1111/jpc.16239&rft_dat=%3Cproquest_pubme%3E2763420556%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2763420556&rft_id=info:pmid/36250562&rfr_iscdi=true |